Bifogade filer
Invitation to SynAct's interim report Q4 2023 presentation
Kurs & Likviditet
Prenumeration
Beskrivning
| Land | Sverige |
|---|---|
| Lista | Small Cap Stockholm |
| Sektor | Hälsovård |
| Industri | Bioteknik |
SynAct Pharma AB (publ) ("SynAct") will publish its Q4 report for 2023 on February 23 at 07.30 CET.
The company will host a conference call and online presentation on the same day at 15.00 CET. Torbjørn Bjerke, CEO, CFO Björn Westberg and Chief Business Officer Jim Knight will give an update on the development progress and financial results and will include a Q&A. The presentation will be made available on the website following the event.
The webcast will be live via the link: https://ir.financialhearings.com/synact-pharma-q4-2023/register
If you wish to participate via teleconference, please register on the link below. After registration you will be provided phone numbers and a conference ID to access the conference. You can ask questions verbally via the teleconference.
https://conference.financialhearings.com/teleconference/?id=5003879
For further information, please contact:
Torbjørn Bjerke
CEO, SynAct Pharma AB
Phone: +46 727 44 41 58
Email: TBJE@synactpharma.com
Email: investor.relations@synactpharma.com